CHS-114

DRUG2 trials

Sponsors

Coherus Oncology, Inc.

Conditions

Advanced Solid TumorHead and Neck Squamous Cell CarcinomaMetastatic Solid Tumor

Phase 1

Study of CHS-114 in Participants With Advanced Solid Tumors

RecruitingNCT05635643

Coherus Oncology, Inc.Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma

Start: 2022-12-15End: 2027-01-01Target: 87Updated: 2026-03-19

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

RecruitingNCT06657144

Coherus Oncology, Inc.Advanced Solid Tumor, Metastatic Solid Tumor

Start: 2025-04-01End: 2028-01-01Target: 154Updated: 2026-03-31

Related Papers

CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses.

2025-12-22

Abstract CT038: Phase 1 study of anti-CCR8 antibody CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumors

Cancer Research2025-04-25

Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-012 citations

1354 Anti-CCR8 antibody CHS-114 (SRF114) depletes tumor-infiltrating regulatory T cells in dissociated tumors from patients with head and neck squamous cell carcinoma

Regular and Young Investigator Award Abstracts2023-10-311 citations